Cited by 309Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration Mechanisms

The DOI matches its Crossref record; 91 of the 91 references it cites were found in a registry or an index.

GFAP as a Potential Biomarker for Alzheimer’s Disease: A Systematic Review and Meta-Analysis

Open access

Kim, Ka Young, Shin, Ki Young, Chang, Keun-A·2023·Cells

DOI 10.3390/cells12091309PMC PMC10177296

Open this paper in CoChat — free account Open PDF

Abstract

Blood biomarkers have been considered tools for the diagnosis, prognosis, and monitoring of Alzheimer's disease (AD). Although amyloid-β peptide (Aβ) and tau are primarily blood biomarkers, recent studies have identified other reliable candidates that can serve as measurable indicators of pathological conditions. One such candidate is the glial fibrillary acidic protein (GFAP), an astrocytic cytoskeletal protein that can be detected in blood samples. Increasing evidence suggests that blood GFAP levels can be used to detect early-stage AD. In this systematic review and meta-analysis, we aimed to evaluate GFAP in peripheral blood as a biomarker for AD and provide an overview of the evidence regarding its utility. Our analysis revealed that the GFAP level in the blood was higher in the Aβ-positive group than in the negative groups, and in individuals with AD or mild cognitive impairment (MCI) compared to the healthy controls. Therefore, we believe that the clinical use of blood GFAP measurements has the potential to accelerate the diagnosis and improve the prognosis of AD.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.3390/cells12091309

Cites

91 of 91 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
Inflammation and Alzheimer’s disease
Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514
Amyloid Precursor Protein Processing and Alzheimer's Disease
O'Brien, R. J., & Wong, P. C. (2011) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-061010-113613 · Cited by 2,061
Amyloid-β and tau--a toxic pas de deux in Alzheimer’s disease
Ittner, L. M., & Götz, J. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn2967 · Cited by 1,269
Blood-based biomarkers for Alzheimer's disease: towards clinical implementation
Teunissen, C. E., Verberk, I. M. W., Thijssen, E. H., Vermunt, L., Hansson, O., Zetterberg, H., van der Flier, W. M., Mielke, M. M., & del Campo, M. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00361-6 · Cited by 1,045
Glial fibrillary acidic protein (GFAP) and the astrocyte intermediate filament system in diseases of the central nervous system
Hol, E. M., & Pekny, M. (2015) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2015.02.004 · Cited by 917
Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer’s Disease
Khan, S., Barve, K. H., & Kumar, M. S. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200528142429 · Cited by 820
A systemic view of Alzheimer disease — insights from amyloid-β metabolism beyond the brain
Wang, J., Gu, B. J., Masters, C. L., & Wang, Y.-J. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.111 · Cited by 808
Blood GFAP as an emerging biomarker in brain and spinal cord disorders
Abdelhak, A., Foschi, M., Abu-Rumeileh, S., Yue, J. K., D’Anna, L., Huss, A., Oeckl, P., Ludolph, A. C., Kuhle, J., Petzold, A., et al. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-021-00616-3 · Cited by 807
A declaração PRISMA 2020: diretriz atualizada para relatar revisões sistemáticas
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T., Mulrow, C. D., Shamseer, L., Tetzlaff, J., Akl, E. A., Brennan, S., et al. (2022) · Revista Panamericana de Salud Pública · doi:10.26633/rpsp.2022.112 · Cited by 761
Neuroinflammation as a common feature of neurodegenerative disorders
Guzman-Martinez, L., Maccioni, R. B., Andrade, V., Navarrete, L. P., Pastor, M. G., & Ramos-Escobar, N. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01008 · Cited by 702
Redefining the concept of reactive astrocytes as cells that remain within their unique domains upon reaction to injury
Wilhelmsson, U., Bushong, E. A., Price, D. L., Smarr, B. L., Phung, V., Terada, M., Ellisman, M. H., & Pekny, M. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0602841103 · Cited by 643 · cited 1×
“In pathological situations, astrocytes undergo a series of morphological and functional alterations collectively referred to as reactive astrocytes and overexpress proteins, such as GFAP [22].”
Background
Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the Alzheimer disease continuum.
Benedet, A. L., Milà-Alomà, M., Vrillon, A., Ashton, N. J., Pascoal, T. A., Lussier, F., Karikari, T. K., Hourregue, C., Cognat, E., Dumurgier, J., et al. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2021.3671 · Cited by 638
Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers
Frisoni, G. B., Boccardi, M., Barkhof, F., Blennow, K., Cappa, S., Chiotis, K., Démonet, J.-F., Garibotto, V., Giannakopoulos, P., Gietl, A., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30159-x · Cited by 626
Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer's disease
Pereira, J. B., Janelidze, S., Smith, R., Mattsson-Carlgren, N., Palmqvist, S., Teunissen, C. E., Zetterberg, H., Stomrud, E., Ashton, N. J., Blennow, K., et al. (2021) · Brain · doi:10.1093/brain/awab223 · Cited by 598
Inconsistencies and Controversies Surrounding the Amyloid Hypothesis of Alzheimer's Disease
Morris, G. P., Clark, I. A., & Vissel, B. (2014) · Acta Neuropathologica Communications · doi:10.1186/s40478-014-0135-5 · Cited by 522
Current state of Alzheimer’s fluid biomarkers
Molinuevo, J. L., Ayton, S., Batrla, R., Bednar, M. M., Bittner, T., Cummings, J., Fagan, A. M., Hampel, H., Mielke, M. M., Mikulskis, A., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1932-x · Cited by 518
The role of astrocytes in amyloid production and Alzheimer's disease
Frost, G. R., & Li, Y. (2017) · Open Biology · doi:10.1098/rsob.170228 · Cited by 448
Evidence for Astrocytosis in Prodromal Alzheimer Disease Provided by 11 C-Deuterium-L-Deprenyl: A Multitracer PET Paradigm Combining 11 C-Pittsburgh Compound B and 18 F-FDG
Carter, S. F., Schöll, M., Almkvist, O., Wall, A., Engler, H., Långström, B., & Nordberg, A. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.110.087031 · Cited by 442
Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer’s disease
Chatterjee, P., Pedrini, S., Stoops, E., Goozee, K., Villemagne, V. L., Asih, P. R., Verberk, I. M. W., Dave, P., Taddei, K., Sohrabi, H. R., et al. (2021) · Translational Psychiatry · doi:10.1038/s41398-020-01137-1 · Cited by 439
Astrocyte phenotype in relation to Alzheimer‐type pathology in the ageing brain
Simpson, J. E., Ince, P. G., Lace, G., Forster, G., Shaw, P. J., Matthews, F., Savva, G., Brayne, C., & Wharton, S. B. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.05.015 · Cited by 381
Astrocyte Biomarkers in Alzheimer’s Disease
Carter, S. F., Herholz, K., Rosa-Neto, P., Pellerin, L., Nordberg, A., & Zimmer, E. R. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.11.006 · Cited by 355
Glial Fibrillary Acidic Protein in Serum is Increased in Alzheimer’s Disease and Correlates with Cognitive Impairment
Oeckl, P., Halbgebauer, S., Anderl-Straub, S., Steinacker, P., Huss, A. M., Neugebauer, H., von Arnim, C. A. F., Diehl-Schmid, J., Grimmer, T., Kornhuber, J., et al. (2019) · Journal of Alzheimer’s Disease · doi:10.3233/jad-180325 · Cited by 345
The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease
Simrén, J., Leuzy, A., Karikari, T. K., Hye, A., Benedet, A. L., Lantero‐Rodriguez, J., Mattsson, N., Schöll, M., Mecocci, P., Vellas, B. J., et al. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12283 · Cited by 344
Plasma Aβ42/40 ratio, p‐tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross‐sectional and longitudinal study in the AIBL cohort
Chatterjee, P., Pedrini, S., Doecke, J. D., Thota, R. N., Villemagne, V. L., Doré, V., Singh, A. K., Wang, P., Rainey‐Smith, S. R., Fowler, C. J., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12724 · Cited by 331
Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment
Cicognola, C., Janelidze, S., Hertze, J., Zetterberg, H., Blennow, K., Mattsson, N., & Hansson, O. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00804-9 · Cited by 324
Beyond the GFAP-Astrocyte Protein Markers in the Brain
Jurga, A. M., Paleczna, M., Kadluczka, J., & Kuter, K. Z. (2021) · Biomolecules · doi:10.3390/biom11091361 · Cited by 319
Neuroglia in neurodegeneration
Heneka, M. T., Rodriguez, J. J., & Verkhratsky, A. (2009) · Brain Research Reviews · doi:10.1016/j.brainresrev.2009.11.004 · Cited by 316
Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimer’s disease
Rodriguez‐Vieitez, E., Saint‐Aubert, L., Carter, S. F., Almkvist, O., Farid, K., Schöll, M., Chiotis, K., Þórðardóttir, S., Graff, C., Wall, A. E., et al. (2016) · Brain · doi:10.1093/brain/awv404 · Cited by 307
Biomarkers for Alzheimer's Disease Diagnosis
Vasileios, M., & Alexiou, A. T. (2017) · Current Alzheimer Research · doi:10.2174/1567205014666170203125942 · Cited by 297
A Review of Fluid Biomarkers for Alzheimer’s Disease: Moving from CSF to Blood
Blennow, K. (2017) · Neurology and Therapy · doi:10.1007/s40120-017-0073-9 · Cited by 295
Combination of plasma amyloid beta(1-42/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology
Verberk, I. M. W., Thijssen, E., Koelewijn, J., Mauroo, K., Vanbrabant, J., de Wilde, A., Zwan, M. D., Verfaillie, S. C. J., Ossenkoppele, R., Barkhof, F., et al. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00682-7 · Cited by 258
Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer’s disease
Chatterjee, P., Pedrini, S., Ashton, N. J., Tegg, M., Goozee, K., Singh, A. K., Karikari, T. K., Simrén, J., Vanmechelen, E., Armstrong, N. J., et al. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12447 · Cited by 231
Inhibition of tau phosphorylating protein kinase cdk5 prevents β‐amyloid‐induced neuronal death
Alvarez, A. R., Toro, R., Cáceres, A., & Maccioni, R. B. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)01279-x · Cited by 228
Diagnostic Accuracy of Plasma Glial Fibrillary Acidic Protein for Differentiating Intracerebral Hemorrhage and Cerebral Ischemia in Patients with Symptoms of Acute Stroke
Foerch, C., Niessner, M., Back, T., Bauerle, M., Marchis, G. M. D., Ferbert, A., Grehl, H., Hamann, G. F., Jacobs, A. H., Kastrup, A., et al. (2011) · Clinical Chemistry · doi:10.1373/clinchem.2011.172676 · Cited by 211
Recent Progress in Alzheimer’s Disease Research, Part 3: Diagnosis and Treatment
Hane, F. T., Robinson, M. J., Lee, B. Y., Bai, O., Leonenko, Z., & Albert, M. S. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-160907 · Cited by 211
Measurement of Glial Fibrillary Acidic Protein in Human Blood: Analytical Method and Preliminary Clinical Results
Missler, U., Wiesmann, M., Wittmann, G., Magerkurth, O., & Hagenström, H. (1999) · Clinical Chemistry · doi:10.1093/clinchem/45.1.138 · Cited by 204
Differential levels of plasma biomarkers of neurodegeneration in Lewy body dementia, Alzheimer’s disease, frontotemporal dementia and progressive supranuclear palsy
Chouliaras, L., Thomas, A., Malpetti, M., Donaghy, P., Kane, J., Mak, E., Savulich, G., Prats-Sedano, M. A., Heslegrave, A. J., Zetterberg, H., et al. (2022) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2021-327788 · Cited by 199
Diagnostic value of plasma p-tau181, NfL, and GFAP in a clinical setting cohort of prevalent neurodegenerative dementias
Baiardi, S., Quadalti, C., Mammana, A., Dellavalle, S., Zenesini, C., Sambati, L., Pantieri, R., Polischi, B., Romano, L., Suffritti, M., et al. (2022) · Alzheimer's Research & Therapy · doi:10.1186/s13195-022-01093-6 · Cited by 193
Plasma biomarkers and genetics in the diagnosis and prediction of Alzheimer’s disease
Stevenson‐Hoare, J. O., Heslegrave, A., Leonenko, G., Fathalla, D., Bellou, E., Luckcuck, L., Marshall, I. J., Sims, R., Morgan, B. P., Hardy, J., et al. (2022) · Brain · doi:10.1093/brain/awac128 · Cited by 191
Drug delivery to the brain in Alzheimer's disease: Consideration of the blood–brain barrier
Banks, W. A. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.12.005 · Cited by 184
Plasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia
Heller, C., Foiani, M. S., Moore, K., Convery, R., Bocchetta, M., Neason, M., Cash, D. M., Thomas, D., Greaves, C. V., Woollacott, I. O., et al. (2020) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2019-321954 · Cited by 182
An accurate fully automated panel of plasma biomarkers for Alzheimer's disease
Palmqvist, S., Stomrud, E., Cullen, N. C., Janelidze, S., Manuilova, E., Jethwa, A., Bittner, T., Eichenlaub, U., Suridjan, I., Kollmorgen, G., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12751 · Cited by 166
Characterisation of the Diagnostic Window of Serum Glial Fibrillary Acidic Protein for the Differentiation of Intracerebral Haemorrhage and Ischaemic Stroke
Dvorak, F., Haberer, I., Sitzer, M., & Foerch, C. (2008) · Cerebrovascular Diseases · doi:10.1159/000172632 · Cited by 163
Biomarkers for Alzheimer’s Disease Early Diagnosis
Ausó, E., Gómez‐Vicente, V., & Esquiva, G. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10030114 · Cited by 159
Comparison of serum neurodegenerative biomarkers among hospitalized COVID‐19 patients versus non‐COVID subjects with normal cognition, mild cognitive impairment, or Alzheimer's dementia
Frontera, J. A., Boutajangout, A., Masurkar, A. V., Betensky, R. A., Ge, Y., Vedvyas, A., Debure, L., Moreira, A., Lewis, A., Huang, J., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12556 · Cited by 157
Early astrocytosis in autosomal dominant Alzheimer’s disease measured in vivo by multi-tracer positron emission tomography
Schöll, M., Carter, S. F., Westman, E., Rodriguez‐Vieitez, E., Almkvist, O., Þórðardóttir, S., Wall, A. E., Graff, C., Långström, B., & Nordberg, A. K. (2015) · Scientific Reports · doi:10.1038/srep16404 · Cited by 153
Reactive astrogliosis: A friend or foe in the pathogenesis of Alzheimer’s disease
Kumar, A., Fontana, I. C., & Nordberg, A. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.15565 · Cited by 150
Astrocytosis precedes amyloid plaque deposition in Alzheimer APPswe transgenic mouse brain: a correlative positron emission tomography and in vitro imaging study
Rodriguez‐Vieitez, E., Ni, R., Gulyás, B. Z., Tóth, M., Häggkvist, J., Halldin, C., Voytenko, L. P., Marutle, A., & Nordberg, A. K. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-015-3047-0 · Cited by 149
The accuracy and robustness of plasma biomarker models for amyloid PET positivity
Benedet, A. L., Brum, W. S., Hansson, O., Initiative, A. D. N., Karikari, T. K., Zimmer, E. R., Zetterberg, H., Blennow, K., & Ashton, N. J. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00942-0 · Cited by 147
Remote Blood Biomarkers of Longitudinal Cognitive Outcomes in a Population Study
Rajan, K. B., Aggarwal, N. T., McAninch, E. A., Weuve, J., Barnes, L. L., Wilson, R. S., DeCarli, C. S., & Evans, D. A. (2020) · Annals of Neurology · doi:10.1002/ana.25874 · Cited by 146
Association of plasma glial fibrillary acidic protein (GFAP) with neuroimaging of Alzheimer's disease and vascular pathology
Shir, D., Graff‐Radford, J., Hofrenning, E. I., Lesnick, T. G., Przybelski, S. A., Lowe, V. J., Knopman, D. S., Petersen, R. C., Jack, C. R., Vemuri, P., et al. (2022) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12291 · Cited by 128
Caspase-Mediated Cleavage of Glial Fibrillary Acidic Protein within Degenerating Astrocytes of the Alzheimer's Disease Brain
Mouser, P. E., Head, E., Ha, K.-H., & Rohn, T. T. (2006) · American Journal Of Pathology · doi:10.2353/ajpath.2006.050798 · Cited by 121
Blood Levels of Glial Fibrillary Acidic Protein (GFAP) in Patients with Neurological Diseases
Mayer, C. A., Brunkhorst, R., Niessner, M., Pfeilschifter, W., Steinmetz, H., & Foerch, C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062101 · Cited by 119
Serum Glial Fibrillary Acidic Protein (GFAP) Is a Marker of Disease Severity in Frontotemporal Lobar Degeneration
Benussi, A., Ashton, N. J., Karikari, T. K., Gazzina, S., Premi, E., Benussi, L., Ghidoni, R., Rodriguez, J. L., Emeršič, A., Binetti, G., et al. (2020) · Journal of Alzheimer’s Disease · doi:10.3233/jad-200608 · Cited by 113
Serum glial fibrillary acidic protein is a body fluid biomarker: A valuable prognostic for neurological disease – A systematic review
Heimfarth, L., Passos, F. R. S., Monteiro, B. S., Araújo, A. A. D. S., Quintans‐Júnior, L. J., & Quintans, J. D. S. S. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108624 · Cited by 107
Association of plasma biomarkers, p‐tau181, glial fibrillary acidic protein, and neurofilament light, with intermediate and long‐term clinical Alzheimer's disease risk: Results from a prospective cohort followed over 17 years
Stocker, H. R., Beyer, L., Perna, L., Rujescu, D., Holleczek, B., Beyreuther, K. T., Stockmann, J., Schöttker, B., Gerwert, K. B., & Brenner, H. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12614 · Cited by 103
Angiotensin converting enzyme and endothelial nitric oxide synthase DNA polymorphisms and late onset Alzheimer's disease
Álvarez, R., Álvarez, V., Lahoz, C. H., Martinez, C., Pena, J., Sanchez, J. M., Guisasola, L. M., Salas‐Puig, J., Morís, G., Vidal, J. A. C., et al. (1999) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.67.6.733 · Cited by 98
Serum GFAP differentiates Alzheimer’s disease from frontotemporal dementia and predicts MCI-to-dementia conversion
Oeckl, P., Anderl-Straub, S., Von Arnim, C. A. F., Baldeiras, I., Diehl-Schmid, J., Grimmer, T., Halbgebauer, S., Kort, A. M., Lima, M., Marques, T. M., et al. (2022) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2021-328547 · Cited by 94
Differential diagnostic performance of a panel of plasma biomarkers for different types of dementia
Thijssen, E. H., Verberk, I. M. W., Kindermans, J., Abramian, A., Vanbrabant, J., Ball, A. J., Pijnenburg, Y. A. L., Lemstra, A. W., van der Flier, W. M., Stoops, E., et al. (2022) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12285 · Cited by 89
Current Biomarkers for Alzheimer’s Disease: From CSF to Blood
Zou, K., Abdullah, M., & Michikawa, M. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10030085 · Cited by 87
Biomarkers for Alzheimer’s Disease
Guzman-Martinez, L., Maccioni, R. B., Farías, G. A., Fuentes, P., & Navarrete, L. P. (2019) · Current Alzheimer Research · doi:10.2174/1567205016666190517121140 · Cited by 87
Body Fluid Biomarkers for Alzheimer’s Disease—An Up-To-Date Overview
Bălașa, A. F., Chircov, C., & Grumezescu, A. M. (2020) · Biomedicines · doi:10.3390/biomedicines8100421 · Cited by 86
Astrogliosis and episodic memory in late life: higher GFAP is related to worse memory and white matter microstructure in healthy aging and Alzheimer's disease
Bettcher, B. M., Olson, K. E., Carlson, N. E., McConnell, B. V., Boyd, T. D., Adame, V., Solano, D. A., Anton, P. E., Markham, N. E., Thaker, A. A., et al. (2021) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2021.02.012 · Cited by 84
Differences between blood and cerebrospinal fluid glial fibrillary Acidic protein levels: The effect of sample stability
Simrén, J., Weninger, H., Brum, W. S., Khalil, S., Benedet, A. L., Blennow, K., Zetterberg, H., & Ashton, N. J. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12806 · Cited by 83
Plasma Glial Fibrillary Acidic Protein Levels Differ Along the Spectra of Amyloid Burden and Clinical Disease Stage1
Asken, B. M., Elahi, F. M., Joie, R. L., Strom, A., Staffaroni, A. M., Lindbergh, C. A., Apple, A. C., You, M. Y., Weiner‐Light, S., Brathaban, N., et al. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200755 · Cited by 81
Amyloid‐beta misfolding and GFAP predict risk of clinical Alzheimer's disease diagnosis within 17 years
Beyer, L., Stocker, H., Rujescu, D., Holleczek, B., Stockmann, J., Nabers, A., Brenner, H., & Gerwert, K. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.12745 · Cited by 81
Association of CSF, Plasma, and Imaging Markers of Neurodegeneration With Clinical Progression in People With Subjective Cognitive Decline
Ebenau, J. L., Pelkmans, W., Verberk, I. M. W., Verfaillie, S. C. J., van den Bosch, K. A., van Leeuwenstijn, M., Collij, L. E., Scheltens, P., Prins, N. D., Barkhof, F., et al. (2022) · Neurology · doi:10.1212/wnl.0000000000200035 · Cited by 77
Inflammatory plasma biomarkers in subjects with preclinical Alzheimer’s disease
Prins, S., de Kam, M. L., Teunissen, C. E., & Groeneveld, G. J. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01051-2 · Cited by 76
Development of Alzheimer’s Disease Biomarkers: From CSF- to Blood-Based Biomarkers
Mankhong, S., Kim, S., Lee, S., Kwak, H., Park, D., Joa, K., & Kang, J. (2022) · Biomedicines · doi:10.3390/biomedicines10040850 · Cited by 72
3H-Deprenyl and 3H-PIB autoradiography show different laminar distributions of astroglia and fibrillar β-amyloid in Alzheimer brain
Marutle, A., Gillberg, P.-G., Bergfors, A., Yu, W., Ni, R., Nennesmo, I., Voytenko, L., & Nordberg, A. (2013) · Journal of Neuroinflammation · doi:10.1186/1742-2094-10-90 · Cited by 70
GFAP and S100B Protein are Associated with Discharged NIHSS of Anterior Circulation Ischemic Stroke
Surjawan, Y., As’ád, S., Ranakusuma, T., & Wijaya, A. (2012) · The Indonesian Biomedical Journal · doi:10.18585/inabj.v4i2.170 · Cited by 60
Looking for novel, brain-derived, peripheral biomarkers of neurological disorders
Chmielewska, N., Szyndler, J., Makowska, K., Wojtyna, D., Maciejak, P., & Płaźnik, A. (2018) · Neurologia i Neurochirurgia Polska · doi:10.1016/j.pjnns.2018.02.002 · Cited by 55
Combining plasma phospho-tau and accessible measures to evaluate progression to Alzheimer’s dementia in mild cognitive impairment patients
Binette, A. P., Palmqvist, S., Bali, D., Farrar, G., Buckley, C. J., Wolk, D. A., Zetterberg, H., Blennow, K., Janelidze, S., & Hansson, O. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-00990-0 · Cited by 54
Diagnostic Biomarkers for Alzheimer’s Disease Using Non-Invasive Specimens
Paraskevaidi, M., Allsop, D., Karim, S., Martin, F. L., & Crean, S. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061673 · Cited by 51
Alzheimer’s Disease Biomarkers Revisited From the Amyloid Cascade Hypothesis Standpoint
Alawode, D. O. T., Fox, N. C., Zetterberg, H., & Heslegrave, A. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.837390 · Cited by 41
Advantages and Pitfalls in Fluid Biomarkers for Diagnosis of Alzheimer’s Disease
Omar, S. H., & Preddy, J. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10030063 · Cited by 40
Blood Phosphorylated Tau 181 as a Biomarker for Amyloid Burden on Brain PET in Cognitively Healthy Adults
McGrath, E. R., Beiser, A., O’Donnell, A., Yang, Q., Ghosh, S., Gonzales, M. M., Himali, J. J., Satizábal, C. L., Johnson, K. A., Tracy, R. P., et al. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-215639 · Cited by 37
Brain-Derived Exosomal Proteins as Effective Biomarkers for Alzheimer’s Disease: A Systematic Review and Meta-Analysis
Kim, K. Y., Shin, K. Y., & Chang, K. (2021) · Biomolecules · doi:10.3390/biom11070980 · Cited by 36
Self-citation
Reactive astrogliosis is associated with higher cerebral glucose consumption in the early Alzheimer’s continuum
Salvadó, G., Milà-Alomà, M., Shekari, M., Ashton, N. J., Operto, G., Falcon, C., Cacciaglia, R., Minguillon, C., Fauria, K., Niñerola-Baizán, A., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05897-4 · Cited by 36
Plasma NfL and GFAP as biomarkers of spinal cord degeneration in adrenoleukodystrophy
van Ballegoij, W. J. C., van de Stadt, S. I. W., Huffnagel, I. C., Kemp, S., Willemse, E. A. J., Teunissen, C. E., & Engelen, M. (2020) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51188 · Cited by 35
Development of molecular tools for diagnosis of Alzheimer’s disease that are based on detection of amyloidogenic proteins
Kulichikhin, K. Y., Fedotov, S. A., Rubel, M. S., Zalutskaya, N. M., Zobnina, A. E., Malikova, O. A., Незнанов, Н. Г., Chernoff, Y. O., & Rubel, A. A. (2021) · Prion · doi:10.1080/19336896.2021.1917289 · Cited by 34
Blood biomarkers for dementia in Hispanic and non‐Hispanic White adults
Gonzales, M. M., Short, M. I., Satizábal, C. L., Bryant, S. O., Tracy, R. P., Zare, H., & Seshadri, S. S. (2021) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12164 · Cited by 30
Evaluation of Eight Plasma Proteins as Candidate Blood-Based Biomarkers for Malignant Gliomas
Lange, R. P., Everett, A., Dulloor, P., Korley, F. K., Bettegowda, C., Blair, C., Grossman, S. A., & Holdhoff, M. (2014) · Cancer Investigation · doi:10.3109/07357907.2014.933237 · Cited by 27
Tau proteins in blood as biomarkers of Alzheimer’s disease and other proteinopathies
Verde, F. (2022) · Journal of Neural Transmission · doi:10.1007/s00702-022-02471-y · Cited by 26
Longitudinal Changes in Blood Biomarkers of Clinical Alzheimer Disease in a Biracial Population Sample
Rajan, K. B., McAninch, E. A., Aggarwal, N. T., Barnes, L. L., Wilson, R. S., Weuve, J., DeCarli, C. S., & Evans, D. A. (2022) · Neurology · doi:10.1212/wnl.0000000000201289 · Cited by 25
Real‐world applicability of glial fibrillary acidic protein and neurofilament light chain in Alzheimer's disease
Parvizi, T., König, T., Wurm, R., Silvaieh, S., Altmann, P., Klotz, S., Rommer, P. S., Furtner, J., Regelsberger, G., Lehrner, J., et al. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.887498 · Cited by 25
Utility of Animal Models to Understand Human Alzheimer’s Disease, Using the Mastermind Research Approach to Avoid Unnecessary Further Sacrifices of Animals
Qin, T., Prins, S., Groeneveld, G. J., van Westen, G. J. P., de Vries, H. E., Wong, Y. C., Bischoff, L. J. M., & de Lange, E. C. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093158 · Cited by 24
Blood biomarkers for cognitive decline and clinical progression in a Mexican American cohort
Gonzales, M. M., Wang, C., Short, M. I., Parent, D. M., Kautz, T. F., MacCarthy, D., Satizábal, C. L., González, D. A., Royall, D. R., Zare, H., et al. (2022) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12298 · Cited by 19
Plasma Glial Fibrillary Acidic Protein Levels Differ Along the Spectra of Amyloid Burden and Clinical Disease Stage
Asken, B. M., Elahi, F. M., Joie, R. L., Strom, A., Staffaroni, A. M., Lindbergh, C. A., Apple, A. C., You, M. Y., Weiner‐Light, S., Brathaban, N., et al. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-219001 · Cited by 18
Blutbasierte Biomarker zur Optimierung der Früh- und Differentialdiagnostik der Alzheimer-Demenz
Hansen, N., Rauter, C. M., & Wiltfang, J. (2022) · Fortschritte der Neurologie · Psychiatrie · doi:10.1055/a-1839-6237 · Cited by 10

Flagged first, then by citations

Research works printed but not linked: 2

Page, 2022, The PRISMA 2020 statement: An updated guideline for reporting systematic reviewsDeclaracion PRISMA 2020: Una guia actualizada para la publicacion de revisiones sistematicas, Rev. Panam. Salud Publica, 46, e112
Hansen, 2022, Blood Based Biomarker for Optimization of Early and Differential Diagnosis of Alzheimer’s Dementia, Fortschr. Neurol. Psyc, 90, 326

Sorted by citations

Neuroinflammation in Alzheimer disease
Heneka, M. T., van der Flier, W. M., Jessen, F., Hoozemanns, J., Thal, D. R., Boche, D., Brosseron, F., Teunissen, C., Zetterberg, H., Jacobs, A. H., et al. (2025) · Nature Reviews Immunology · doi:10.1038/s41577-024-01104-7 · Cited by 638
Challenges in the practical implementation of blood biomarkers for Alzheimer’s disease
Schöll, M., Verberk, I. M. W., del Campo, M., Delaby, C., Therriault, J., Chong, J. R., Palmqvist, S., & Alcolea, D. A. (2024) · The Lancet Healthy Longevity · doi:10.1016/j.lanhl.2024.07.013 · Cited by 150
Biomimetic Nanovesicles as a Dual Gene Delivery System for the Synergistic Gene Therapy of Alzheimer’s Disease
Jiang, S., Cai, G., Yang, Z., Shi, H., Zeng, H., Ye, Q., Hu, Z., & Wang, Z. (2024) · ACS Nano · doi:10.1021/acsnano.3c13150 · Cited by 135
Therapeutic potential of human microglia transplantation in a chimeric model of CSF1R-related leukoencephalopathy
Chadarevian, J. P., Hasselmann, J., Lahian, A., Capocchi, J. K., Escobar, A., Lim, T. E., Le, L., Tu, C., Nguyen, J., Kiani Shabestari, S., et al. (2024) · Neuron · doi:10.1016/j.neuron.2024.05.023 · Cited by 83
Neuroinflammatory fluid biomarkers in patients with Alzheimer’s disease: a systematic literature review
Heneka, M. T., Gauthier, S. G., Chandekar, S. A., Hahn-Pedersen, J. H., Bentsen, M. A., & Zetterberg, H. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-02939-9 · Cited by 97

See all 309

Authors: Kim, K. Y., Shin, K. Y., & Chang, K.-A.
Affiliations: Gachon University (KR)
Seoul National University (KR)
Corresponding author: Shin, Ki Young
Chang, Keun-A
ORCID: Kim, Ka Young
Shin, Ki Young
Chang, Keun-A
Venue: Cells
Publisher: MDPI AG
Published: 2023-05-04
Volume: 12
Issue: 9
Pages: 1309
ISSN: 2073-4409 (ISSN-L)
DOI: 10.3390/cells12091309
PMC: PMC10177296
OpenAlex: W4376630140
Cited by: 309
References: 91
Citations by year: 2026: 93 · 2025: 126 · 2024: 80 · 2023: 10
FWCI: 14.11
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by
creativecommons.org/licenses/by/4.0/ (vor)
Locations: Cells (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders: National Research Foundation of Korea (NRF) (2022R1A2C1092597, 2020R1I1A1A01070793)
Basic Science Research Program through the NRF of Korea (2022R1A2C1092597, 2020R1I1A1A01070793)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords: glial fibrillary acidic protein, Alzheimer's disease, blood biomarkers, peripheral blood, amyloid-beta, mild cognitive impairment, early diagnosis, prognosis, astrocytes
MeSH terms: Alzheimer Disease, Glial Fibrillary Acidic Protein, Humans, Biomarkers, Amyloid beta-Peptides, Cognitive Dysfunction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

GFAP as a Potential Biomarker for Alzheimer’s Disease: A Systematic Review and Meta-Analysis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks